The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab

• Published in: British journal of haematology Vol. 162; no. 4; pp. 547 - 548
• Main Authors: Alderman, Charles, Corlett, Jonathan, Cullis, Jonathan
• Format: Journal Article
• Language: English
• Published: Oxford Blackwell 01.08.2013
• Subjects: Administration, Intranasal; Aerosols; Aged; anaemia; Anemias. Hemoglobinopathies; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - economics; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - economics; Antibodies, Monoclonal, Humanized - therapeutic use; antibody therapy; Bevacizumab; Biological and medical sciences; bleeding disorders; Cautery; Combined Modality Therapy; Diseases of red blood cells; Drug Evaluation; Epistaxis - drug therapy; Epistaxis - etiology; Epistaxis - surgery; Female; Hematologic and hematopoietic diseases; Humans; Lasers, Dye - therapeutic use; Male; Medical sciences; Nasal Mucosa - drug effects; Recurrence; Telangiectasia, Hereditary Hemorrhagic - complications; Tumors; vascular endothelial growth factor; Antineoplastic agent; Nose disease; Relapse; Cardiovascular disease; Hemopathy; Monoclonal antibody; Hemorrhage; Bevacizumab; Telangiectasia; Vascular disease; bleeding disorders; Cancerology; ENT disease; Antiangiogenic agent; anaemia; Hematology; Anemia; Intranasal administration; Hereditary; Epistaxis; Vascular endothelium growth factor; Treatment; vascular endothelial growth factor; Coagulopathy; antibody therapy
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.12377